These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 427822)

  • 41. [Allergic reaction to melphalan].
    Bleichner F; Mende S
    Onkologie; 1982 Aug; 5(4):195. PubMed ID: 6755332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Melphalan-related leukemia in multiple myeloma.
    Wahlin A; Roos G; Rudolphi O; Holm J
    Acta Med Scand; 1982 May; 211(3):203-8. PubMed ID: 7080865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.
    Woodhouse KW; Hamilton P; Lennard A; Rawlins MD
    Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.
    Bosanquet AG; Gilby ED
    Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

  • 47. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.
    Gera S; Musch E; Osterheld HK; Loos U
    Cancer Chemother Pharmacol; 1989; 23(2):76-80. PubMed ID: 2910515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure.
    Pecherstorfer M; Zimmer-Roth I; Weidinger S; Irsigler K; Halbmayer WM; Ulrich W; Fischer M; Baumgartner G
    Clin Investig; 1994 Jul; 72(7):522-5. PubMed ID: 7981581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral complications of high-dose melphalan in multiple myeloma.
    Barrett AP; Buckley DJ
    Oral Surg Oral Med Oral Pathol; 1987 Aug; 64(2):264-7. PubMed ID: 3476906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The systemic administration of intravenous melphalan.
    Sarosy G; Leyland-Jones B; Soochan P; Cheson BD
    J Clin Oncol; 1988 Nov; 6(11):1768-82. PubMed ID: 3054005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intermittent melphalan therapy in multiple myeloma.
    Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
    JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
    [No Abstract]   [Full Text] [Related]  

  • 52. Is more better?
    Cooper MR
    Cancer Invest; 1992; 10(1):93-4. PubMed ID: 1735015
    [No Abstract]   [Full Text] [Related]  

  • 53. Pulmonary histopathologic changes associated with melphalan therapy.
    Taetle R; Dickman PS; Feldman PS
    Cancer; 1978 Sep; 42(3):1239-45. PubMed ID: 359122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Myeloma with hypereosinophilia. Eosinophil reaction following melphalan].
    Ozgüven O; Sebik F; Basci A
    Presse Med; 1983 Mar; 12(11):704. PubMed ID: 6220307
    [No Abstract]   [Full Text] [Related]  

  • 55. [Acute, reversible, interstitial pneumopathy induced by melphalan].
    Lioté H; Gauthier JF; Prier A; Gauthier-Rahman S; Kaplan G; Akoun G
    Rev Mal Respir; 1989; 6(5):461-4. PubMed ID: 2690210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leukaemia on myeloma.
    Webb JA; Bateman CJ; Davies JD
    Br Med J; 1971 Oct; 4(5781):231. PubMed ID: 5286613
    [No Abstract]   [Full Text] [Related]  

  • 57. Leukemia on myeloma.
    Quirt IC; Hart GD; Soots M
    Br Med J; 1972 Jan; 1(5794):248. PubMed ID: 4500986
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.
    Bosanquet AG; Gilby ED
    Cancer Chemother Pharmacol; 1984; 12(3):183-6. PubMed ID: 6705135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Leukaemia and cytotoxic drugs.
    Lancet; 1971 Jan; 1(7689):70-1. PubMed ID: 4099223
    [No Abstract]   [Full Text] [Related]  

  • 60. Fatal drug reactions among medical inpatients.
    Shapiro S; Slone D; Lewis GP; Jick H
    JAMA; 1971 Apr; 216(3):467-72. PubMed ID: 5107928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.